Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28856012 | 0.73 | HSD17B10 (0.50) | LMNAHSD17B10CA12CA1CA2 | |
| SCHEMBL7866877 | 0.72 | HSD17B10 (0.50) | LMNAHSD17B10CA12CA1CA2 | |
| SCHEMBL8194412 | 0.72 | HSD17B10 (0.50) | LMNAHSD17B10CA12CA1CA2 | |
| SCHEMBL7081515 | 0.71 | KDM4E (0.46) | LMNAHSD17B10CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL7019349 | 0.71 | HSD17B10 (0.49) | LMNAHSD17B10CA12CA1CA2 | |
| SCHEMBL11224907 | 0.70 | HSD17B10 (0.48) | LMNAHSD17B10CA12CA1CA2 | |
| SCHEMBL443306 | 0.70 | CA12 (0.56) | LMNAHSD17B10CA12CA1CA2 | |
| SCHEMBL8625346 | 0.69 | HSD17B10 (0.47) | LMNAHSD17B10CA12CA1CA2 | |
| SCHEMBL31377271 | 0.69 | ALDH1A1 (0.58) | PKMKMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL29111666 | 0.69 | LMNA (0.54) | LMNAHSD17B10CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230159-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
| US-11046716-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200055877-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
| US-10399996-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-09-03 | — | — | US | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| WO-2017044828-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-16 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | LMNA 2956/4885HSD17B10 2919/4885CA12 3716/4885 |
| US-10399996-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | LMNA 542/4885HSD17B10 913/4885CA12 2857/4885 |
| US-20170073360-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | LMNA 542/4885HSD17B10 913/4885CA12 2857/4885 |
| US-20200055877-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | LMNA 542/4885HSD17B10 913/4885CA12 2857/4885 |
| US-11046716-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | LMNA 542/4885HSD17B10 913/4885CA12 2857/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | LMNA 2956/4885HSD17B10 2919/4885CA12 3716/4885 |
| US-20250230159-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | KRAS, HRAS, NRAS | LMNA 3903/4885HSD17B10 3593/4885CA12 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.